RareKids-CAN Offer Subsidized Services for Investigator-initiated Academic Clinical Trials
RareKids-CAN offers a range of subsidized services for investigator-initiated (academic-led) pediatric rare disease clinical trials. The goal of these services is to stretch project funds further, ensuring greater impact and cost savings. Below is the list of subsidized services offered:
100% Subsidized Services (RareKids-CAN will cover 100% of the cost of the following services):
-
- Consultations: We will conduct a robust consultation to identify areas of needs for your project with valuable involvement from relevant sub platforms based on your project needs to ensure your project receives adequate support.
- High-level project management: An experienced project manager will ensure efficient coordination, oversight, and successful execution from inception to completion for your clinical trial.
- Database build (not including management): We will provide project-specific electronic case report form (e-CRF) development and database management in a validated REDCap database housed at the Women and Children’s Health Research Institute (WCHRI).
- Data Safety Monitoring Board: From our repository of individuals with specific expertise relevant to your project, we facilitate a centralized data safety monitoring board to ensure participant safety and provide expertise on clinical trial conduct for continuation, modification, or termination.
50% Subsidized Services (RareKids-CAN will cover 50% of the total cost of the following services):
-
- Regulatory submissions: We assist study teams in the preparation and submission of clinical trial applications, investigational testing authorizations, and single-patient study applications for regulated clinical trials to Health Canada. We will also assist in adverse event reporting.
- Monitoring: We have a dedicated and experienced monitoring team to perform risk-based remote and on-site monitoring to meet the Health Canada required sponsor obligations.
All other services are 100% cost recovered (i.e., RareKids-CAN will not subsidize)
If you have a clinical trial that require these services or would like to further discuss, you can complete the project intake form.
Read next...
NMD4C Investigators Awarded $5.7 Million as Part of National Team to Advance 3D Models for Brain and Neuromuscular Research
NMD4C investigators are part of a national research team awarded $5.7 million in Canada Foundation for Innovation (CFI) infrastructure funding to support the development of advanced 3D human tissue models for brain and neuromuscular research. The initiative brings together researchers from The Ottawa Hospital, the University of Ottawa, and the University of Toronto, and is co‑led by NMD4C investigator Dr. Michael Rudnicki, alongside Dr. Penney Gilbert and Dr. Mireille Khacho. This shared infrastructure will enable cutting‑edge neuromuscular and neural tissue research, accelerate discovery, and provide hands‑on training opportunities for trainees across Canada.
Sixth Annual NMD4C and MDC Clinical Fellowship Competition from Opens May 1st
Together, NMD4C and MDC are excited to open our 2027 annual funding competition to provide clinical fellowship award(s) in neuromuscular medicine and electromyography (EMG)! This annual funding competition provides one-year salary support ($80,000) for early-career clinicians to participate in Canadian neuromuscular medicine and EMG fellowship training programs.
Advancing Neuromuscular Research: MDC Awards $700k to Seven NMD4C Investigator-Led Projects
We’re proud to share that neuromuscular research led by our NMD4C Investigators and Leads; Dr. Hanns Lochmüller, Dr. Rashmi Kothary, Dr. Rami Massie, Dr. Elise Duchesne, Dr. Omid Kiamanesh, and Dr. Nicolas Dumont, have been recognized in Muscular Dystrophy Canada’s 2026 Neuromuscular Clinical and Translational Research Grant announcement. Drawing from MDC’s national funding update, we’re…